Kromozome

Kromozome Therapeutics is a preclinical-stage biotechnology company focused on developing a proprietary non-viral platform for the delivery of large genetic payloads. The company's technology aims to address the cargo capacity limitations of traditional viral vector systems, such as Adeno-associated virus (AAV), by enabling the transport of full-length genes and complex genetic circuits exceeding 5 kilobases. This approach is designed to provide more effective treatments for complex genetic conditions and neurodegenerative diseases that are currently underserved by existing gene therapy methods. Based in San Jose, California, Kromozome is led by a team of experienced drug developers and scientists dedicated to expanding the reach of genomic medicine through innovative delivery solutions.